SS1(dsFv)PE38 clinical trials
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2000
How each study uses SS1(dsFv)PE38 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- SS1(dsFv)-PE38 immunotoxin
- 2
Studies by the year they started
5 studies that test it; most in 2000 (2)
| Year | Studies |
|---|---|
| 2000 | 2 |
| 2001 | 1 |
| 2003 | 1 |
| 2009 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 3
National Cancer Institute (NCI) (3) · INSYS Therapeutics Inc (2)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses SS1(dsFv)PE38 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung AdenocarcinomaCompletedPhase 1National Cancer Institute (NCI)NCT01051934Written as SS1 (dsFv) PE38How we know
- Immunotoxin Therapy in Treating Patients With Advanced CancerCompletedPhase 1National Cancer Institute (NCI)NCT00006981Written as SS1(dsFv)-PE38 immunotoxinHow we know
- Immunotoxin Therapy in Treating Patients With Advanced Solid TumorsCompletedPhase 1National Cancer Institute (NCI)NCT00066651Written as SS1(dsFv)-PE38 immunotoxinHow we know
- Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 DaysWithdrawnPhase 1INSYS Therapeutics IncNCT00024674Written as SS1(dsFv)-PE38How we know
- Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six DosesWithdrawnPhase 1INSYS Therapeutics IncNCT00024687Written as SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin ImmunotoxinHow we know